IP Library › Granted Patent US 7,939,631
Granted Patent B2
US 7,939,631 · App. 12/715,045 · Granted May 10, 2011

APO-2 receptor polypeptides

Assignee: Genentech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,939,631
App. No.
12/715,045
Granted
May 10, 2011
Kind
B2
Abstract

Novel polypeptides, designated Apo-2, which are capable of modulating apoptosis are provided. Compositions including Apo-2 chimeras, nucleic acid encoding Apo-2, and antibodies to Apo-2 are also provided.

Claims (35)

1. A fusion protein comprising a polypeptide consisting of SEQ ID NO:1 fused to a heterologous polypeptide.

2. The fusion protein of claim 1 wherein said heterologous polypeptide amino acid sequence is an epitope tag.

3. The fusion protein of claim 2 wherein said epitope tag is placed at a carboxyl-terminus of said polypeptide.

4. The fusion protein of claim 2 wherein said epitope tag is selected from the group consisting of flu HA tag, c-myc tag, Herpes Simplex virus glycoprotein D tag, Flag-polypeptide tag, KT3 epitope peptide tag, α-tubulin epitope peptide tag and T7 gene 10 protein peptide tag.

5. The fusion protein of claim 4 wherein said epitope tag is Flag-polypeptide tag.

6. The fusion protein of claim 1 wherein said heterologous polypeptide is an immunoglobulin, immunoglobulin chain, or fragment thereof.

7. The fusion protein of claim 6 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is selected from the group consisting of IgG, IgE, IgA, IgM and IgD.

8. The fusion protein of claim 7 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is an IgG.

9. A fusion protein comprising a polypeptide consisting of amino acid residues 1 to 182 of SEQ ID NO:1 fused to a heterologous polypeptide.

10. The fusion protein of claim 9 wherein said heterologous polypeptide is an epitope tag.

11. The fusion protein of claim 10 wherein said epitope tag is placed at a carboxyl-terminus of said polypeptide.

12. The fusion protein of claim 10 wherein said epitope tag is selected from the group consisting of flu HA tag, c-myc tag, Herpes Simplex virus glycoprotein D tag, Flag-polypeptide tag, KT3 epitope peptide tag, α-tubulin epitope peptide tag and T7 gene 10 protein peptide tag.

13. The fusion protein of claim 12 wherein said epitope tag is Flag-polypeptide tag.

14. The fusion protein of claim 9 wherein said heterologous polypeptide is an immunoglobulin, immunoglobulin chain, or fragment thereof.

15. The fusion protein of claim 14 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is selected from the group consisting of IgG, IgE, IgA, IgM and IgD.

16. The fusion protein of claim 15 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is an IgG.

17. A fusion protein comprising a polypeptide encoded by the cDNA contained in ATCC Deposit No. 209021 fused to a heterologous polypeptide.

18. The fusion protein of claim 17 wherein said heterologous polypeptide-is an epitope tag.

19. The fusion protein of claim 18 wherein said epitope tag is placed at a carboxyl-terminus of said polypeptide.

20. The fusion protein of claim 18 wherein said epitope tag is selected from the group consisting of flu HA tag, c-myc tag, Herpes Simplex virus glycoprotein D tag, Flag-polypeptide tag, KT3 epitope peptide tag, α-tubulin epitope peptide tag and T7 gene 10 protein peptide tag.

21. The fusion protein of claim 20 wherein said epitope tag is Flag-polypeptide tag.

22. The fusion protein of claim 18 wherein said heterologous polypeptide is an immunoglobulin, immunoglobulin chain, or fragment thereof.

23. The fusion protein of claim 22 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is selected from the group consisting of IgG, IgE, IgA, IgM and IgD.

24. The fusion protein of claim 23 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is an IgG.

25. A fusion protein comprising:

(i) a polypeptide that binds to Apo-2 ligand and has at least 95% amino acid sequence identity with SEQ ID NO:1; and

(2) a heterologous polypeptide,

wherein the heterologous polypeptide is fused to the polypeptide having at least 95% amino acid sequence identity with SEQ ID NO:1.

26. The fusion protein of claim 25 wherein said heterologous polypeptide is an epitope tag.

27. The fusion protein of claim 26 wherein said epitope tag is placed at a carboxyl-terminus of said polypeptide.

28. The fusion protein of claim 26 wherein said epitope tag-is selected from the group consisting of flu HA tag, c-myc tag, Herpes Simplex virus glycoprotein D tag, Flag-polypeptide tag, KT3 epitope peptide tag, α-tubulin epitope peptide tag and T7 gene 10 protein peptide tag.

29. The fusion protein of claim 28 wherein said epitope tag is Flag-polypeptide tag.

30. The fusion protein of claim 25 wherein said heterologous polypeptide is an immunoglobulin, immunoglobulin chain, or fragment thereof.

31. The fusion protein of claim 30 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is selected from the group consisting of IgG, IgE, IgA, IgM and IgD.

32. The fusion protein of claim 31 wherein said immunoglobulin, immunoglobulin chain, or fragment thereof is an IgG.

Continuity (8)
Division 11245053 · Oct 7, 2005
Division 10423448 · Apr 25, 2003
Continuation 10288917 · Nov 6, 2002
Continuation 10052798 · Nov 2, 2001
Division 09079029 · May 14, 1998
Provisional Application 60046615 · May 15, 1997
Provisional Application 60074119 · Feb 9, 1998
Related Publication 20110009599A1 · Jan 13, 2011